Dipsogenic diabetes insipidus

Summary

Dipsogenic diabetes insipidus (MONDO:0022993) is a disease and 6 clinical trials. Top therapeutic interventions include dulaglutide and urea. A subtype of diabetes insipidus — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	dipsogenic diabetes insipidus
Mondo ID	MONDO:0022993
MeSH	C548013
DOID	DOID:0081058
NCIT	C129735
SNOMED CT	82800008
UMLS	C0268813
MedGen	82829
Is cancer (heuristic)	no

Also known as: Dipsogenic diabetes insipidus · dipsogenic diabetes insipidus · primary polydipsia

Disease family

This is a subtype of diabetes insipidus. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › kidney disorder › diabetes insipidus › dipsogenic diabetes insipidus

Related subtypes (3): neurohypophyseal diabetes insipidus, nephrogenic diabetes insipidus, gestational diabetes insipidus

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	5
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02770885	PHASE2	COMPLETED	Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia (The GOLD-Study)
NCT06604975	Not specified	NOT_YET_RECRUITING	Arginin-stimulated Copeptin in Polyuria-polydipsia Syndrome in Children
NCT07569861	Not specified	NOT_YET_RECRUITING	Copeptin Measurement After Mannitol and Hypertonic Saline for the Diagnosis of Polyuria-polydipsia Syndrome
NCT01940614	Not specified	COMPLETED	Use of Copeptin in Diabetes Insipidus
NCT05890690	Not specified	COMPLETED	Plasma Copeptin in Response to Oral Urea in Healthy Adults and Patients With Polyuria-polydipsia Syndrome
NCT06542198	Not specified	COMPLETED	Mannitol-induced Release of Copeptin in Healthy Adults and Patients With Polyuria-Polydipsia Syndrome (MARS Study)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DULAGLUTIDE	4	1
UREA	4	1